We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Roche Holdings Ltd AG (QX) | USOTC:RHHBY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.20 | 3.03% | 40.76 | 40.59 | 40.80 | 40.80 | 40.12 | 40.15 | 2,775,124 | 22:20:00 |
From Jul 2022 to Jul 2024
By Pierre Bertrand
Roche Holding AG said Monday that Phase 3 Graduate studies of gantenerumab, for treatment of early Alzheimer's disease, failed to meet its primary endpoints.
The Swiss pharma company said the drug failed to slow patients' clinical decline and that the drug's removal of beta-amyloid, a protein that builds up to make plaques in the brains of people with Alzheimer's disease, was lower than expected.
The company said it would keep working on novel diagnostics and treatments for Alzheimer's and said it would present at the Clinical Trials on Alzheimer's Disease Conference.
Write to Pierre Bertrand at pierre.bertrand@wsj.com
(END) Dow Jones Newswires
November 14, 2022 01:51 ET (06:51 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Roche (QX) Chart |
1 Month Roche (QX) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
